Compounds > 3-acetylindole
Page last updated: 2024-11-05

3-acetylindole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Acetylindole is an indole derivative that has been studied for its potential biological activities. It is synthesized through the acetylation of indole, typically using acetic anhydride in the presence of a catalyst. Research has shown that 3-acetylindole exhibits a range of pharmacological effects, including anti-inflammatory, anti-cancer, and antioxidant properties. Its anti-inflammatory activity has been attributed to its ability to inhibit the production of pro-inflammatory cytokines. 3-acetylindole has also been shown to suppress the growth of various cancer cell lines, suggesting its potential as a therapeutic agent. The compound's antioxidant properties are related to its ability to scavenge free radicals, thus protecting cells from oxidative damage. Due to these promising properties, 3-acetylindole has become a subject of considerable research interest, particularly in the areas of drug development and medicinal chemistry.'

3-acetylindole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12802
CHEMBL ID553944
SCHEMBL ID50742
MeSH IDM0525437

Synonyms (58)

Synonym
AC-4559
3-indolyl methyl ketone
0hat270v6u ,
unii-0hat270v6u
5-21-08-00297 (beilstein handbook reference)
3-acetyl indole
1-(1h-indol-3-yl)ethan-1-one
nsc-47180
ketone, indol-3-yl methyl
3-acetyl-1h-indole
3-acetylindole
ethanone, 1-(1h-indol-3-yl)-
703-80-0
nsc47180
acetyl-3-indole
nsc 47180
indol-3-yl methyl ketone
ai3-51299
nsc 58084
brn 0122579
acetyl-3-indole [french]
einecs 211-875-5
nsc-58084
nsc58084
wln: t56 bmj dv1
AN-068/40177744
1-(1h-indol-3-yl)ethanone
3-acetylindole, practical grade
3-acetylindole, 98%
A-1380
A0849
AKOS000269096
CHEMBL553944 ,
F1727-0313
STK802653
1-(1h-indol-3-yl)-ethanone
FT-0614887
AM20050446
AB00460
AB00375940-03
SCHEMBL50742
CG-0523
mfcd00005626
SY003989
DTXSID10220570
1-(1h-indol-3-yl)ethanone #
STR01618
1-(1~{h}-indol-3-yl)ethanone
5rn ,
ethanone, 1-(1h-indol-3-yl)- (9ci)
8mq ,
NCGC00320872-01
BCP26519
Q27236784
W10344
bdbm50591351
CS-W019453
EN300-36200
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein polybromo-1Homo sapiens (human)Kd1,195.00000.02501.01155.8000AID1857770
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
mitotic cell cycleProtein polybromo-1Homo sapiens (human)
chromatin remodelingProtein polybromo-1Homo sapiens (human)
regulation of transcription by RNA polymerase IIProtein polybromo-1Homo sapiens (human)
negative regulation of cell population proliferationProtein polybromo-1Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionProtein polybromo-1Homo sapiens (human)
positive regulation of T cell differentiationProtein polybromo-1Homo sapiens (human)
positive regulation of cell differentiationProtein polybromo-1Homo sapiens (human)
positive regulation of myoblast differentiationProtein polybromo-1Homo sapiens (human)
regulation of G0 to G1 transitionProtein polybromo-1Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleProtein polybromo-1Homo sapiens (human)
positive regulation of double-strand break repairProtein polybromo-1Homo sapiens (human)
regulation of nucleotide-excision repairProtein polybromo-1Homo sapiens (human)
transcription elongation by RNA polymerase IIProtein polybromo-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
DNA bindingProtein polybromo-1Homo sapiens (human)
chromatin bindingProtein polybromo-1Homo sapiens (human)
protein bindingProtein polybromo-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nuclear chromosomeProtein polybromo-1Homo sapiens (human)
kinetochoreProtein polybromo-1Homo sapiens (human)
chromatinProtein polybromo-1Homo sapiens (human)
nucleusProtein polybromo-1Homo sapiens (human)
nucleoplasmProtein polybromo-1Homo sapiens (human)
nuclear matrixProtein polybromo-1Homo sapiens (human)
RSC-type complexProtein polybromo-1Homo sapiens (human)
SWI/SNF complexProtein polybromo-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
AID1857771Binding affinity to 15N-labeled recombinant human PBRM1 BD2 transfected in Escherichia coli BL21 (DE3) assessed as thermal stabilization by measuring change in melting temperature at 100 uM by SYPRO orange dye based differential scanning fluorimetry analy2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening.
AID430495Enhancement of BMP-2 expression in mouse MC3T3-E1 cells assessed as upregulation rate at 4 uM2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Synthesis and evaluation of 1-(benzo[b]thiophen-2-yl)ethanone analogues as novel anti-osteoporosis agents acting on BMP-2 promotor.
AID1780506Inverse agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity by hybrid reporter gene assay2021Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20
Development and Profiling of Inverse Agonist Tools for the Neuroprotective Transcription Factor Nurr1.
AID1857770Binding affinity to 15N-labeled recombinant human PBRM1 BD2 transfected in Escherichia coli BL21 (DE3) assessed as 1H/13N chemical shift perturbation by measuring dissociation constant by NMR titration analysis2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's6 (54.55)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.28 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index32.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-hydroxybenzaldehyde
[no description available]		2.0810hydroxybenzaldehydeEC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor;
mouse metabolite;
plant metabolite
catechol
[no description available]		2.0810catecholsallelochemical;
genotoxin;
plant metabolite
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		2.0810monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
amodiaquine
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.		2.3110aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
lobenzarit
lobenzarit: prevents autoimmune kidney disease in hybrid mice; RN given refers to parent cpd		2.4110aminobenzoic acid
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		2.05101-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
benzoxazolone
benzoxazolone: RN given refers to parent cpd; structure. 2-benzoxazolinone : A member of the class of benzoxazoles that is 2,3-dihydro-1,3-benzoxazole carrying an oxo group at position 2.		2.0810benzoxazoleallelochemical;
phytoalexin
4-nitrobenzoic acid
4-nitrobenzoic acid: RN given refers to parent cpd. 4-nitrobenzoic acid : A nitrobenzoic acid having the nitro group at the 4-position.		2.0810nitrobenzoic acid
trifluoroacetic acid
Trifluoroacetic Acid: A very strong halogenated derivative of acetic acid. It is used in acid catalyzed reactions, especially those where an ester is cleaved in peptide synthesis.. trifluoroacetic acid : A monocarboxylic acid that is the trifluoro derivative of acetic acid.		2.0710fluoroalkanoic acidhuman xenobiotic metabolite;
NMR chemical shift reference compound;
reagent
3-methylsalicylic acid
3-methylsalicylic acid : A monohydroxybenzoic acid consisting of salicylic acid carrying a methyl group at the 3-position.		2.0810monohydroxybenzoic acidbacterial xenobiotic metabolite
1,5-dihydroxynaphthalene
[no description available]		2.0810
5-methylsalicylic acid
[no description available]		2.0810
4,4'-dihydroxybiphenyl
biphenyl-4,4'-diol : A member of the class of hydroxybiphenyls that is biphenyl with hydroxy groups at positions 4 and 4'.		2.0810hydroxybiphenyls
benzothiazole
benzothiazole: structure. benzothiazole : An organic heterobicyclic compound that is a fusion product between benzene and thiazole. The parent of the class of benzothiazoles.		2.0810benzothiazolesenvironmental contaminant;
plant metabolite;
xenobiotic
phenylhydrazine
[no description available]		2.0810phenylhydrazinesxenobiotic
dibenzothiazyl disulfide
dibenzothiazyl disulfide: vulcanizing accelerant. dibenzothiazol-2-yl disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of two molecules of 1,3-benzothiazole-2-thiol. It is used as an accelerator in the rubber industry.		2.0810benzothiazoles;
organic disulfide		allergen
2-aminobenzothiazole
[no description available]		2.0810benzothiazoles
thiazoles
[no description available]		2.05101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
4-methylcatechol
[no description available]		2.0810methylcatecholantioxidant;
carcinogenic agent;
hapten;
human metabolite;
plant metabolite
ninhydrin
Ninhydrin: 2,2-Dihydroxy-1H-indene-1,3-(2H)-dione. Reagent toxic to skin and mucus membranes. It is used in chemical assay for peptide bonds, i.e., protein determinations and has radiosensitizing properties.. ninhydrin : A member of the class of indanones that is indane-1,3-dione bearing two additional hydroxy substituents at position 2.		2.0810aromatic ketone;
beta-diketone;
indanones;
ketone hydrate		colour indicator;
human metabolite
indole-3-carbaldehyde
indole-3-carbaldehyde: metabolite of tryptophan; structure. indole-3-carbaldehyde : A heteroarenecarbaldehyde that is indole in which the hydrogen at position 3 has been replaced by a formyl group.		2.5220heteroarenecarbaldehyde;
indole alkaloid;
indoles		bacterial metabolite;
human xenobiotic metabolite;
marine metabolite;
plant metabolite
hydroxyhydroquinone
benzene-1,2,4-triol : A benzenetriol carrying hydroxy groups at positions 1, 2 and 4.		2.0810benzenetriolmouse metabolite
6-hydroxyquinoline
quinolin-6-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 6.		2.0810monohydroxyquinoline
2,7-dihydroxynaphthalene
[no description available]		2.0810
pentafluorobenzoic acid
[no description available]		2.0810perfluorinated compound
1,3-indandione
1,3-indandione : A member of the class of indanones that is indane in which the hydrogens at positions 2 and 4 have been replaced by oxo groups.		2.0810aromatic ketone;
beta-diketone;
indanones
5-methylbenzimidazole
5-methylbenzimidazole: structure in first source. 5-methyl-1H-benzimidazole : A member of the class of imidazoles that is 1H-benzimidazole in which the hydrogen at position 5 is substituted by a methyl group.		2.0810imidazoles
2-hydrazinobenzothiazole
[no description available]		2.0810
2-hydroxybenzothiazole
2-hydroxybenzothiazole : Benzothiazole substituted with a hydroxy group at the 2-position.		2.0810benzothiazole
phenylhydroquinone
phenylhydroquinone: major metabolite of o-phenylphenol; cleaves DNA; structure given in first source		2.0810
2-amino-4-methylbenzothiazole
2-amino-4-methylbenzothiazole: structure in first source		2.0810
2-acetylbenzofuran
2-acetylbenzofuran: structure in first source		2.0510
2,2'-biphenol
biphenyl-2,2'-diol : A member of the class of hydroxybiphenyls carrying hydroxy groups at positions 2 and 2'.		2.0810hydroxybiphenyls
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		2.0510delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
salicylhydroxamic acid
[no description available]		2.0810hydroxamic acid;
phenols		antibacterial drug;
EC 1.11.2.2 (myeloperoxidase) inhibitor;
EC 3.5.1.5 (urease) inhibitor;
trypanocidal drug
5-fluorosalicylic acid
5-fluorosalicylic acid: structure given in first source; product from action of alkaline phosphatase on 5-fluorosalicyl phosphate; forms highly fluorescent terbium ternary complex		2.0810
1,8-diaminonaphthalene
1,8-diaminonaphthalene: structure in first source		2.0810
4(5)-phenylimidazole
4(5)-phenylimidazole: tautomeric cpd; cytochrome P450 14alpha-sterol demethylase, CYP51 antagonist		2.0810
indole-3-carboxylic acid
indole-3-carboxylic acid : An indole-3-carboxylic acid carrying a carboxy group at position 3.		2.3110indol-3-yl carboxylic acidbacterial metabolite;
human metabolite
biphenyl-2-carboxylic acid
biphenyl-2-carboxylic acid: structure in first source		2.0810
4-Methoxybenzamide
[no description available]		2.0810benzamides
2-(carboxymethylthio)benzothiazole
2-(carboxymethylthio)benzothiazole: oxidation product of 2-(hydroxyethylthio)benzothiazole; structure given in first source		2.0810
2-acetylbenzothiophene
2-acetylbenzothiophene: metabolite of zileuton; structure in first source		2.0510
2,6-dihydroxynaphthalene
[no description available]		2.0810naphthols
benzo(b)thiophene-2-carboxylic acid
benzo(b)thiophene-2-carboxylic acid: for prevention of osteoporosis; structure given in first source		2.0510
bis(i,i-trifluoroacetoxy)iodobenzene
phenyliodine(III) bis(trifluoroacetate): structure in first source		2.0710
methyl indole-3-carboxylate
methyl indole-3-carboxylate : The methyl ester of indole-3-carboxylic acid.		2.3110indoles;
methyl ester		metabolite
captax
captax: RN given refers to parent cpd. 1,3-benzothiazole-2-thiol : 1,3-Benzothiazole substituted at the 2-position with a sulfanyl group.		2.0810aryl thiol;
benzothiazoles		carcinogenic agent;
metabolite
2,4-Di(3-pyridyl)-1,3-thiazole
[no description available]		2.4110thiazoles
5-Methyl-6-(2-thienyl)-2,3,4,5-tetrahydropyridazin-3-one
[no description available]		2.4110pyridazines
4-nitrocatechol
4-nitrocatechol : A member of the class of catechols that is benzene-1,2-diol substituted by a nitro group at position 4.It is the by-product of the hydroxylation of p-nitrophenol.		2.0810C-nitro compound;
catechols		human xenobiotic metabolite;
lipoxygenase inhibitor
esculetin
esculetin: used in filters for absorption of ultraviolet light; structure. esculetin : A hydroxycoumarin that is umbelliferone in which the hydrogen at position 6 is substituted by a hydroxy group. It is used in filters for absorption of ultraviolet light.		2.0810hydroxycoumarinantioxidant;
plant metabolite;
ultraviolet filter
7-hydroxycoumarin-4-acetic acid
7-hydroxycoumarin-4-acetic acid: pH-indicator dye; structure in first source		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Age-Related Osteoporosis
[description not available]		02.0510
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		02.0510
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Cancer of Prostate
[description not available]		02.4110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.4110
Herpes Simplex Virus Infection
[description not available]		02.0510
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		02.0510